95 related articles for article (PubMed ID: 26845607)
1. Monozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?
Grove JI; Austin M; Tibble J; Aithal GP; Verma S
Ann Hepatol; 2016; 15(2):277-82. PubMed ID: 26845607
[TBL] [Abstract][Full Text] [Related]
2. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
Kitamoto A; Kitamoto T; Nakamura T; Ogawa Y; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Nakao K; Sekine A; Chayama K; Nakajima A; Hotta K
Endocr J; 2014; 61(7):683-9. PubMed ID: 24785259
[TBL] [Abstract][Full Text] [Related]
3. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.
León-Mimila P; Vega-Badillo J; Gutiérrez-Vidal R; Villamil-Ramírez H; Villareal-Molina T; Larrieta-Carrasco E; López-Contreras BE; Kauffer LR; Maldonado-Pintado DG; Méndez-Sánchez N; Tovar AR; Hernández-Pando R; Velázquez-Cruz R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
Exp Mol Pathol; 2015 Apr; 98(2):178-83. PubMed ID: 25597287
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
[TBL] [Abstract][Full Text] [Related]
5. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
[TBL] [Abstract][Full Text] [Related]
6. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.
Flores YN; Velázquez-Cruz R; Ramírez P; Bañuelos M; Zhang ZF; Yee HF; Chang SC; Canizales-Quinteros S; Quiterio M; Cabrera-Alvarez G; Patiño N; Salmerón J
Mol Biol Rep; 2016 Dec; 43(12):1359-1369. PubMed ID: 27752939
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.
Larrieta-Carrasco E; Flores YN; Macías-Kauffer LR; Ramírez-Palacios P; Quiterio M; Ramírez-Salazar EG; León-Mimila P; Rivera-Paredez B; Cabrera-Álvarez G; Canizales-Quinteros S; Zhang ZF; López-Pérez TV; Salmerón J; Velázquez-Cruz R
Exp Mol Pathol; 2018 Feb; 104(1):50-58. PubMed ID: 29307798
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).
Dold L; Luda C; Schwarze-Zander C; Boesecke C; Hansel C; Nischalke HD; Lutz P; Mohr R; Wasmuth JC; Strassburg CP; Trebicka J; Rockstroh JK; Spengler U
PLoS One; 2017; 12(6):e0178685. PubMed ID: 28594920
[TBL] [Abstract][Full Text] [Related]
9. Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease.
Kahali B; Halligan B; Speliotes EK
Semin Liver Dis; 2015 Nov; 35(4):375-91. PubMed ID: 26676813
[TBL] [Abstract][Full Text] [Related]
10. Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study.
Vespasiani-Gentilucci U; Dell'Unto C; De Vincentis A; Baiocchini A; Delle Monache M; Cecere R; Pellicelli AM; Giannelli V; Carotti S; Galati G; Gallo P; Valentini F; Del Nonno F; Rosati D; Morini S; Antonelli-Incalzi R; Picardi A
Can J Gastroenterol Hepatol; 2018; 2018():7564835. PubMed ID: 29732362
[TBL] [Abstract][Full Text] [Related]
11. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.
Valenti L; Nobili V; Al-Serri A; Rametta R; Leathart JB; Zappa MA; Dongiovanni P; Fracanzani AL; Alterio A; Roviaro G; Daly AK; Fargion S; Day CP
J Hepatol; 2011 Dec; 55(6):1409-14. PubMed ID: 21777557
[TBL] [Abstract][Full Text] [Related]
12. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
[TBL] [Abstract][Full Text] [Related]
13. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
[TBL] [Abstract][Full Text] [Related]
14. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
Vespasiani-Gentilucci U; Gallo P; Porcari A; Carotti S; Galati G; Piccioni L; De Vincentis A; Dell'Unto C; Vorini F; Morini S; Riva E; Picardi A
Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
[TBL] [Abstract][Full Text] [Related]
15. The genetic backgrounds in nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Itoh Y
Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
[TBL] [Abstract][Full Text] [Related]
16. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
17. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.
Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L
Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881
[TBL] [Abstract][Full Text] [Related]
18. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
19. A role for mammalian target of rapamycin (mTOR) pathway in non alcoholic steatohepatitis related-cirrhosis.
Kubrusly MS; Corrêa-Giannella ML; Bellodi-Privato M; de Sá SV; de Oliveira CP; Soares IC; Wakamatsu A; Alves VA; Giannella-Neto D; Bacchella T; Machado MC; D'Albuquerque LA
Histol Histopathol; 2010 Sep; 25(9):1123-31. PubMed ID: 20607654
[TBL] [Abstract][Full Text] [Related]
20. Relationship between N,N-dimethylformamide exposure, PNPLA3, GCKR, COL13A1 and TM6SF2 genes, and liver injury.
Zhang X; Jiang H; Shen J; Zhang Y; Gu Y; Xiao J; Lian Y
Ecotoxicol Environ Saf; 2019 Apr; 171():347-351. PubMed ID: 30616151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
